Xenon Pharmaceuticals
XENE
31 hedge funds and large institutions have $80.8M invested in Xenon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 5 closing their positions.
58.65% more ownership
Funds ownership: 0% → 58.65% (+59%)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 30 → 31 (+1)
0% more capital invested
Capital invested by funds: $80.6M → $80.8M (+$212K)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.57M |
| 2 |
Millennium Management
New York
|
+$1.56M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$803K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$564K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$442K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.12M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$972K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$523K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$388K |
| 5 |
PA
Perceptive Advisors
New York
|
-$181K |
XENE Hedge Fund Activity: Q4 2016 in Review
31 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2016, worth a combined $80.8M — up 0.26% from $80.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.57M. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.12M.
- 31 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2016, up from 30 in Q3 2016.
- Funds reported $80.8M of Xenon Pharmaceuticals stock for Q4 2016, up 0.26% quarter-over-quarter.
- 6 funds opened new Xenon Pharmaceuticals positions in Q4 2016 and 5 closed out, a net change of +1 holder.
- The largest Xenon Pharmaceuticals buyer in Q4 2016 was Capital World Investors, an estimated $1.57M added.
- The largest Xenon Pharmaceuticals seller in Q4 2016 was Highland Capital Management (Texas), an estimated $1.12M sold.
Based on aggregated 13F filings for Q4 2016.